Download PDF
Dtsch Med Wochenschr 2001; 126(38): 1053-1057
DOI: 10.1055/s-2001-17312
Übersichten
© Georg Thieme Verlag Stuttgart · New York

Therapeutische Neoangiogenese

Alternative oder adjuvante Option bei der Behandlung fortgeschrittener koronarer und peripherer ischämischer GefäßerkrankungenTherapeutic neo-angiogenesis: alternative or adjuvant option in the treatment of advanced coronary and peripheral ischaemic vascular diseaseM. G. Engelmann, S. Nikol
  • Medizinische Klinik I (Direktor: Prof. Dr. G. Steinbeck), Ludwig-Maximilians-Universität, Klinikum Großhadern, München
Further Information

Publication History

Publication Date:
20 September 2001 (online)

Also available at
   Permissions and Reprints
Preview

Das therapeutische Potenzial angiogener Wachstumsfaktoren ist seit mehreren Jahrzehnten bekannt [10]. In zahlreichen Untersuchungen konnte für mehrere Gefäßwachstumsfaktoren die Fähigkeit der vermehrten Kapillar- und Kollateralgefäßbildung in Tiermodellen mit myokardialer oder Beinarterienischämie nachgewiesen werden [12]. Diese innovative Form der Behandlung ischämischer Erkrankungen wird als »therapeutische Angiogenese« bezeichnet und könnte als adjuvante oder alternative Behandlung bei fortgeschrittenen Stadien der ischämischen Herzerkrankung oder der peripheren arteriellen Verschlusskrankheit eingesetzt werden.

Literatur

  • 1 www.theheart.org: March 2001
  • 2 Asahara T, Masuda H, Takahashi T. et al . Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.  Circ Res. 1999;  85 221-228
    Search in Google Scholar
  • 3 Asahara T, Murohara T, Sullivan A. et al . Isolation of putative progenitor endothelial cells for angiogenesis.  Science. 1997;  275 964-967
    Search in Google Scholar
  • 4 Baumgartner I, Pieczek A, Manor O. et al . Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia.  Circulation. 1998;  97 1114-1123
    Search in Google Scholar
  • 5 Baumgartner I, Rauh G, Pieczek A. et al . Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor.  Ann Intern Med. 2000;  132 880-884
    Search in Google Scholar
  • 6 Brogi E, Schatteman G, Wu T. et al . Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression.  J Clin Invest. 1996;  97 469-476
    Search in Google Scholar
  • 7 Carmeliet P, Ferreira V, Breier G. et al . Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.  Nature. 1996;  380 435-439
    Search in Google Scholar
  • 8 Chronos N A. The FGF-2 initiating revascularization support trial (FIRST),. ACC Clinical Trials 2000
    Search in Google Scholar
  • 9 Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors.  Nat Med. 1999;  5 1359-1364
    Search in Google Scholar
  • 10 Folkman J. Tumor angiogenesis: Therapeutic implications.  N Engl J Med. 1971;  285 1182-1186
    Search in Google Scholar
  • 11 Henry T D, Annex B H, Azrin M A. et al . Double blind, Placebo controlled trial of recombinant human vascular endothelial growth factor - the VIVA trial.  J Am Coll Cardiol. 1999;  33 384A
    Search in Google Scholar
  • 12 Isner J M. Therapeutic angiogenesis: a new frontier for vascular therapy.  Vasc Med. 1996;  1 79-87
    Search in Google Scholar
  • 13 Isner J M, Baumgartner I, Rauh G. et al . Treatment of thromboangiitis obliterans (Buerger’s disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results.  J Vasc Surg. 1998;  28 964-973
    Search in Google Scholar
  • 14 Isner J M, Pieczek A, Schainfeld R. et al . Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb.  Lancet. 1996;  348 370-374
    Search in Google Scholar
  • 15 Isner J M, Walsh K, Symes J. et al . Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease.  Hum Gene Ther. 1996;  7 959-988
    Search in Google Scholar
  • 16 Kobayashi T, Hamano K, Li T S. et al . Enhancement of angiogenesis by the implantation of self bone marrow cells in a rat ischemic heart model.  J Surg Res. 2000;  89 189-195
    Search in Google Scholar
  • 17 Kornowski R, Fuchs S, Baffour R. et al . Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia.   Eur Heart J. 2000;  21 356
    Search in Google Scholar
  • 18 Laham R J, Chronos N A, Pike M. et al . Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study.  J Am Coll Cardiol. 2000;  36 2132-2139
    Search in Google Scholar
  • 19 Laham R J, Sellke F W, Edelman E R. et al . Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial.  Circulation. 1999;  100 1865-1871
    Search in Google Scholar
  • 20 Laitinen M, Makinen K, Manninen H. et al . Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia.  Hum Gene Ther. 1998;  9 1481-1486
    Search in Google Scholar
  • 21 Lazarous D F, Scheinowitz M, Shou M. et al . Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart.  Circulation. 1995;  91 145-153
    Search in Google Scholar
  • 22 Lazarous D F, Unger E F, Epstein S E. et al . Effect of basic fibroblast growth factor on lower extremity blood flow in patients with intermittent claudication: preliminary results.  Circulation. 1998;  98 I-456
    Search in Google Scholar
  • 23 Lederman R J. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication: Results after 180 days. 50th Congress of the American College of Cardiology. Orlando 2001
    Search in Google Scholar
  • 24 Lehrman S. Virus treatment questioned after gene therapy death.  Nature. 1999;  401 517-518
    Search in Google Scholar
  • 25 Losordo D W, Vale P R, Symes J F. et al . Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.  Circulation. 1998;  98 2800-2804
    Search in Google Scholar
  • 26 Makinen K, Laitinen M, Manninen H. et al . Catheter-mediated VEGF gene transfer to human lower limb arteries after PTA.  Circulation. 1999;  100 I-770
    Search in Google Scholar
  • 27 Neufeld G, Cohen T, Gengrinovitch S. et al . Vascular endothelial growth factor (VEGF) and its receptors.  Faseb J. 1999;  13 9-22
    Search in Google Scholar
  • 28 Nikol S, Engelmann M G, Armeanu S. et al . District-specific influence of vascular endothelial growth factor 165 (VEGF-165) on coronary and peripheral arteries resulting in arteriogenesis or angiogenesis.  Circulation. 1999;  100 I-489
    Search in Google Scholar
  • 29 Papapetropoulos A, Cardena G, Dengler T J. et al . Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors.  Lab Invest. 1999;  79 213-223
    Search in Google Scholar
  • 30 Rauh G, Gravereaux E, Pieczek A. et al . Assessment of safety and efficiency of intramuscular gene therapy with VEGF-2 in patients with critical limb ischemia.  Circulation. 1999;  100 I-770
    Search in Google Scholar
  • 31 Risau W. Mechanisms of angiogenesis.  Nature. 1997;  386 671-674
    Search in Google Scholar
  • 32 Rosengart T K, Lee L Y, Patel S R. et al . Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.  Circulation. 1999;  100 468-474
    Search in Google Scholar
  • 33 Rosengart T K, Lee L Y, Port J L. et al . Video assisted epicardially delivery of angiogenic gene therapy to the human myocardium utilizing an Adenovirus vector encoding for VEGF121.  Circulation. 1999;  100 I-770
    Search in Google Scholar
  • 34 Schaper W, Buschmann I. Collateral circulation and diabetes [editorial].  Circulation. 1999;  99 2224-2226
    Search in Google Scholar
  • 35 Schaper W, Schaper J. Collateral circulation: Heart, brain, kidney, limbs. Dortrecht, Netherlands, Kluwer Academic Publishers 1993
    Search in Google Scholar
  • 36 Schumacher B, Pecher P, von Specht B U. et al . Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease.  Circulation. 1998;  97 645-650
    Search in Google Scholar
  • 37 Sellke F W, Laham R J, Edelman E R. et al RP> . Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results.  Ann Thorac Surg. 1998;  65 1540-1544
    Search in Google Scholar
  • 38 Symes J F, Losordo D W, Vale P R. et al . Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.  Ann Thorac Surg. 1999;  68 830-836
    Search in Google Scholar
  • 39 Takahashi T, Kalka C, Masuda H. et al . Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization.  Nat Med. 1999;  5 434-438
    Search in Google Scholar
  • 40 Unger E F, Goncalves L, Epstein S E. et al . Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris.  Am J Cardiol. 2000;  85 1414-1419
    Search in Google Scholar
  • 41 Vale P R, Losordo D W, Milliken C E. et al . Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia.  Circulation. 2000;  102 965-974
    Search in Google Scholar
  • 42 Waltenberger J. Modulation of growth factor action: implications for the treatment of cardiovascular diseases.  Circulation. 1997;  96 4083-4094
    Search in Google Scholar
  • 43 Wolfe J H, Wyatt M G. Critical and subcritical ischaemia.  Eur J Vasc Endovasc Surg. 1997;  13 578-582
    Search in Google Scholar
  • 44 Yancopoulos G D, Davis S, Gale N W. et al . Vascular-specific growth factors and blood vessel formation.  Nature. 2000;  407 242-248
    Search in Google Scholar
  • 45 Yla-Herttuala S, Martin J F. Cardiovascular gene therapy.  Lancet. 2000;  355 213-222
    Search in Google Scholar

Korrespondenz

Priv.-Doz. Dr. med. Sigrid Nikol

Medizinische Klinik I Klinikum Großhadern

Marchioninistraße 15

81377 München

Phone: 089/7095 0

Fax: 089/7095 6166

Email: s-nikol@gmx.de